167 related articles for article (PubMed ID: 23632960)
21. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDG retention index and biologic prognostic parameters in breast cancer.
García Vicente AM; Castrejón ÁS; Relea Calatayud F; Muñoz AP; León Martín AA; López-Muñiz IC; Del Mar Muñoz Sánchez M; Cordero García JM; Becerra Nakayo EM
Clin Nucl Med; 2012 May; 37(5):460-6. PubMed ID: 22475895
[TBL] [Abstract][Full Text] [Related]
23.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
24. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Vrancken Peeters MJ; Wesseling J; Lips EH; Vogel WV; Aukema TS; van Werkhoven E; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1830-8. PubMed ID: 22895862
[TBL] [Abstract][Full Text] [Related]
25. Reliability of
Jena A; Taneja S; Singh A; Negi P; Sarin R; Das PK; Singhal M
AJR Am J Roentgenol; 2017 Sep; 209(3):662-670. PubMed ID: 28678576
[TBL] [Abstract][Full Text] [Related]
26. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):32-40. PubMed ID: 23929431
[TBL] [Abstract][Full Text] [Related]
27. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.
Koo HR; Park JS; Kang KW; Han W; Park IA; Moon WK
Eur Radiol; 2015 Nov; 25(11):3314-21. PubMed ID: 25903708
[TBL] [Abstract][Full Text] [Related]
28. Combination of breast imaging parameters obtained from
Grapin M; Coutant C; Riedinger JM; Ladoire S; Brunotte F; Cochet A; Humbert O
Eur J Radiol; 2019 Apr; 113():81-88. PubMed ID: 30927964
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
30. Basal ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer.
García Vicente AM; Soriano Castrejón Á; López-Fidalgo JF; Amo-Salas M; Muñoz Sanchez Mdel M; Álvarez Cabellos R; Espinosa Aunión R
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1804-13. PubMed ID: 26156534
[TBL] [Abstract][Full Text] [Related]
31. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
32. PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype.
Catalano OA; Horn GL; Signore A; Iannace C; Lepore M; Vangel M; Luongo A; Catalano M; Lehman C; Salvatore M; Soricelli A; Catana C; Mahmood U; Rosen BR
Br J Cancer; 2017 Mar; 116(7):893-902. PubMed ID: 28208155
[TBL] [Abstract][Full Text] [Related]
33. Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions.
Caprio MG; Cangiano A; Imbriaco M; Soscia F; Di Martino G; Farina A; Avitabile G; Pace L; Forestieri P; Salvatore M
Radiol Med; 2010 Mar; 115(2):215-24. PubMed ID: 20017002
[TBL] [Abstract][Full Text] [Related]
34. Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.
Incoronato M; Grimaldi AM; Cavaliere C; Inglese M; Mirabelli P; Monti S; Ferbo U; Nicolai E; Soricelli A; Catalano OA; Aiello M; Salvatore M
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1680-1693. PubMed ID: 29696443
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic impact of
Arslan E; Çermik TF; Didem Can Trabulus F; Canan Kelten Talu E; Başaran Ş
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(3):147-153. PubMed ID: 30914287
[TBL] [Abstract][Full Text] [Related]
36. ¹⁸F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer.
Champion L; Lerebours F; Cherel P; Edeline V; Giraudet AL; Wartski M; Bellet D; Alberini JL
Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1206-13. PubMed ID: 23640467
[TBL] [Abstract][Full Text] [Related]
37. 18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco‑regional SUVmax with classical prognostic factors.
García García-Esquinas M; García-Sáenz JA; Arrazola García J; Enrique Fuentes Ferrer M; Furió V; Rodriguez Rey C; Román JM; Carreras Delgado JL
Q J Nucl Med Mol Imaging; 2014 Mar; 58(1):66-73. PubMed ID: 24104854
[TBL] [Abstract][Full Text] [Related]
38. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
[TBL] [Abstract][Full Text] [Related]
39. Association between semiquantitative PET parameters and molecular subtypes of breast invasive ductal carcinoma.
Chiacchio S; Evangelista L; Alsharif A; Manca G; DI Martino F; Negri A; Tredici M; Cervino AR; Puccini G; Filidei E; Ghilli M; Naccarato AG; Roncella M; Volterrani D
Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):101-111. PubMed ID: 26329496
[TBL] [Abstract][Full Text] [Related]
40. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
